The COMBAT trial assessed combination CXC chemokine receptor 4 (CXCR4) with pembrolizumab in a phase IIa study of patients with metastatic PDAC, having demonstrated in mouse models that CXCR4 may increase T cell tumour infiltration. This evidence concerns the gene CXCR4 and neoplasm.